PNC-27

• Preclinical studies report HDM-2-dependent membrane-pore formation and rapid necrosis in several cancer-cell models while tested non-transformed controls were less affected
• Activity was reported in p53-null K562 cells, supporting a p53-independent mechanism in that model
• Paclitaxel combination effects were demonstrated in vitro and in a mouse ID8 ovarian-cancer model
• A 2019 study reported activity against human and murine acute-myeloid-leukemia models, including leukemia-stem-cell-enriched populations, while preserving normal hematopoietic stem-cell activity in the tested mouse experiments
• A 2024 cell study also reported mitochondrial-membrane disruption
• None of these findings constitutes human clinical validation.

CAS

1159861-00-3

Formula

C₁₈₈H₂₉₃N₅₃O₄₄S

Molecular weight

4032 g/mol

Appearance

White to off-white lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Follow the released-lot COA and supplier instructions. Unless the batch documentation states otherwise, keep lyophilized material sealed, desiccated and protected from light at or below -20°C; avoid repeated freeze-thaw cycles after reconstitution and define solution stability in the laboratory's validated protocol.

MOQ

1 kit (10 vials) per SKU

Lead time

14–21 days

PNC-27 is a 32-residue chimeric research peptide comprising the HDM-2-binding segment of p53 (residues 12-26) fused to a membrane-residency peptide derived from the Drosophila Antennapedia penetratin sequence. Cell and animal studies report selective lysis in models displaying membrane-associated HDM-2, but this remains preclinical evidence and does not establish efficacy or safety in people. The FDA has not approved PNC-27 for any disease and warned consumers after bacterial contamination was found in marketed inhalation solutions. A 2017 case report described fatal gastrointestinal hemorrhage after experimental treatment; causation was not established.

• Membrane-associated HDM-2 and pore-formation research in pancreatic, breast, melanoma, ovarian and leukemia cell models. p53-independent necrosis research in p53-null K562 leukemia cells
• Ex vivo study of patient-derived epithelial ovarian-cancer cultures
• Combination research with paclitaxel in ID8 cells and a mouse ovarian-cancer model
• Acute-myeloid-leukemia and leukemia-stem-cell research in human and murine preclinical models
• Mitochondrial-membrane disruption research in MIA-PaCa-2 cells
• No published peer-reviewed human interventional trial establishes clinical safety, efficacy, dose or route.

PNC-27 is proposed to bind membrane-associated HDM-2 through its p53-derived domain. PNC-27-HDM-2 complexes then assemble around transmembrane pores, causing rapid loss of membrane integrity and necrotic cell death, a process termed "poptosis" by the authors. The p53-null K562 model supports p53-independent activity. A 2024 MIA-PaCa-2 cell study additionally found PNC-27 on mitochondrial membranes, loss of mitochondrial-dye retention and preserved lysosomal-dye retention. These mechanisms are preclinical and model-dependent.

• PNC-27 is not FDA-approved for any disease
• On January 10, 2017, the FDA warned consumers not to purchase or use PNC-27 after Variovorax paradoxus was found in an inhalation-solution sample
• On March 27, 2017, the FDA reported Ralstonia insidiosa in another inhalation-solution sample
• The FDA stated that contaminated products can cause serious, potentially life-threatening infections and identified young children, older adults, pregnant people and immunocompromised individuals as higher-risk groups
• The warning also documented marketed nebulized, intravenous, vaginal-suppository and rectal-suppository forms, none evaluated or approved as safe and effective by the FDA
• A 2017 ACG case report described massive gastrointestinal hemorrhage and death after experimental PNC-27 treatment, while explicitly leaving causation unresolved
• No peer-reviewed human trial or human pharmacokinetic dataset establishes safety, efficacy, dose or route
• PNC-27 must not replace evidence-based cancer care.

Interactions reported in the literature

• Paclitaxel: preclinical synergy was reported in ID8 cells and a mouse ovarian-cancer model (PMID 28667027)
• Ketone bodies: a claim appears in secondary sources, but no traceable peer-reviewed primary study was identified and it should not be presented as established
• Other HDM-2/MDM2 inhibitors: target overlap is theoretically possible, but no interaction study was identified
• No reliable interaction data were found for thymosin alpha-1, BPC-157, TB-500 or other commonly co-marketed research peptides.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 5 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Require a batch-specific COA that states the exact peptide form, sequence, molecular mass, counterion, purity method and net peptide content
• Confirm identity by an orthogonal mass-spectrometric method rather than relying on HPLC purity alone
• For material intended for cell-based work, define laboratory-appropriate endotoxin and bioburden limits and request the corresponding released-lot results
• Review residual solvents, water content and counterion content when they affect assay concentration
• Reject undocumented sterility claims and any claim that research-grade material is suitable for human use
• Match CAS 1159861-00-3 and PubChem CID 16201774 to the 32-residue free-peptide sequence while confirming the supplied form on the COA.

Follow the released-lot COA and supplier instructions. Unless the batch documentation states otherwise, keep lyophilized material sealed, desiccated and protected from light at or below -20°C; avoid repeated freeze-thaw cycles after reconstitution and define solution stability in the laboratory's validated protocol.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• 1) Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences. 2010;107(5). PMID 20080680; PMCID PMC2836618; doi:10.1073/pnas.0909364107. 2) Bowne WB, et al. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Annals of Surgical Oncology. 2010. PMID 20182728. 3) Davitt K, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science. 2014;44(3):241-248. PMID 25117093. 4) Alagkiozidis I, et al. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer. Annals of Clinical and Laboratory Science. 2017;47(3):271-281. PMID 28667027. 5) Aguon PM, et al. Experimental PNC-27 Therapy and Massive GI Hemorrhage: A Complication or Coincidence? American Journal of Gastroenterology. 2017;112:S1035-S1036. doi:10.14309/00000434-201710001-01880. 6) Kandel ES, et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2019. PMID 31337857. 7) Pincus MR, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomolecules. 2022;12(5):684. PMID 35625682; PMCID PMC9138867. 8) Krzesaj P, et al. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical and Laboratory Science. 2024;54(2):137-148. PMID 38802154.

1. 01

   Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes

   Proceedings of the National Academy of Sciences of the USA (PNAS) · 2010 · peer-reviewed original research

   Open source
2. 02

   The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide

   Cancer Chemotherapy and Pharmacology · 2010 · peer-reviewed original research

   Open source
3. 03

   PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis

   Biomedicines · 2022 · peer-reviewed original research

   Open source
4. 04

   Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption

   Annals of Clinical and Laboratory Science · 2024 · peer-reviewed original research

   Open source
5. 05

   PNC-27 Kills Cervical Cancer Cells but Not Untransformed Cervical Cells, an Effect that is Enhanced by Ketone Bodies

   Medical Research Archives · 2025 · peer-reviewed original research

   Open source
6. 06

   Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer

   Annals of Clinical and Laboratory Science · 2015 · peer-reviewed original research

   Open source
7. 07

   The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells

   Annals of Clinical and Laboratory Science · 2014 · peer-reviewed original research

   Open source
8. 08

   FDA warns cancer patients not to use PNC-27 products for treatment

   U.S. Food and Drug Administration · 2017 · regulatory document (FDA consumer safety warning)

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order